The tweet was deleted by the author.
But we saved everything 🙂.
D-Wave Quantum said it has shown in a peer-reviewed study that annealing quantum computers could boost the performance of generative AI models in drug discovery. The stock edges lower on the day, trading at $16.44.
D-Wave Quantum, working with SHIONOGI_JP, has demonstrated through a peer-reviewed study in Scientific Reports that annealing quantum computers can significantly enhance the performance of generative AI models used in drug discovery. The statement was made directly by D-Wave Quantum through its official account. Generative AI is emerging as a promising technology for the early stages of drug development.
View post on X Loading...
Price is sitting right at support from the weekly low at $16.4. Shares of D-Wave Quantum remain below their MA-20, MA-50, and MA-200, keeping the daily chart structure bearish. RSI at 39.1 is nearing oversold territory, suggesting the recent decline is becoming extended.
Traders should watch for movement away from the weekly low at $16.4 to gauge whether the development is being reflected. Price is testing this support, without making a decisive move through it. The past week featured a sharp move lower without forming a sustained trend, though from here, the downside probability for the coming trading week is more than 80% and the upside probability is less than 20%, with a projected range of $15.58 to $17.29. A close above $18.32 would confirm buyers are responding, while a drop below $16.4 would indicate the move is being faded. On the weekly chart the longer-term picture stays negative.
Previously it was reported that D-Wave Quantum is advancing practical quantum computing solutions for enterprise-scale challenges, focusing on both annealing and gate-model technologies. The recent peer-reviewed findings in generative AI for drug discovery add a tangible application to these efforts, while a decisive move away from the $16.40 support could set the near-term trading direction.